Systematic Reviews
Copyright ©The Author(s) 2025.
World J Clin Cases. Oct 16, 2025; 13(29): 110948
Published online Oct 16, 2025. doi: 10.12998/wjcc.v13.i29.110948
Table 2 Evidencebased intervention modalities for postpartum depression
Modality
Core elements
Key evidence (illustrative)
Target population
Evidence grade
DrugBrexanolone 60 hours IV; zuranolone 14 days oral; conventional SSRIsBrexanolone phaseIII (n = 246): Mean ΔPHQ19 = -17.0 (95%CI: -19.3 to -14.7) within brexanolone arm, -14.5 vs placebo; zuranolone phaseII: Rapid onsetModeratetosevere PPD; lactating mothers with careful evaluationIA
Psychological/psychotherapyCBT (facetoface/online); IPT (partner/group); MBCTCBT metaanalysis 2022 (31 RCTs) SMD -0.62; coupleIPT RCT ΔEPDS -4.1; MBCTPD trial: 50% relapserisk reductionMildtomoderate PPD or women declining drugsIA
Exercise/lifestyle≥ 150 minutes per week moderate aerobic exercise; highfiber diet; vitaminD supplementationSystematic review 2022 (35 studies) RR 0.77; highfiber diet improves gut microbiota & moodWomen ≥ 6 weeks postpartum who are physically ableIB
Integrated/communityCHW “Thinking Healthy” module; digital appbased CBT; WHO mhGAP + group IPTWHO mhGAP + nurseled groupIPT RCT in Nepal: ΔEPDS -4.3Resourcelimited or lowaccess settingsII
Neuromodulation (pilot/protocol)Anodal prefrontal tDCS 2 mA × 20 minutes, 10 sessionsProtocol only: Sun et al[52], 2023 RCT design; planned n = 120, primary outcome ΔEPDS at 4 weeksModerate PPD unresponsive to CBT/SSRINR